ARIZ Precision Medicine

ARIZ Precision Medicine is a private, preclinical-stage biotech founded in 2018 and headquartered in Phoenix, Arizona (with operations noted in Davis, California). The company is developing a precision oncology platform that targets specific PRDM family genes using siRNA therapeutics delivered via a targeted nanotechnology system. With a recently granted broad US patent, a key collaboration with the UK's Nucleic Acid Therapy Accelerator (NATA), and a recent $110,000 angel investment, ARIZ is advancing a multi-indication pipeline focused on major solid and hematologic cancers. Its leadership team combines deep expertise in oncology, RNAi, drug development, and business, including the inventor of pegylation and a Herceptin co-inventor.

Proprietary platform combining siRNA targeting of PRDM family cancer driver genes with a nanotechnology-based Targeted Drug Delivery System (T-DDS) for precise, cell-specific delivery.

ARIZ operates in the highly competitive fields of precision oncology and RNAi therapeutics, competing against large pharma and biotechs with approved drugs and advanced pipelines. Its differentiation hinges on its specific targeting of the PRDM gene family and its proprietary delivery system, but it must prove this advantage against established modalities like small molecules, antibodies, and other oligonucleotide delivery platforms.